Greenwich Lifesciences Inc Cash Flow-to-Debt Ratio
Greenwich Lifesciences Inc cash flow-to-debt ratio. Greenwich Lifesciences Inc (GLSI) has a Cash Flow-to-Debt Ratio of -0.34x as of June 2026, meaning its operating cash flow of $-1.94 Million could theoretically repay 0% of its total liabilities ($5.76 Million) in one year. See financial flexibility index of Greenwich Lifesciences Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Greenwich Lifesciences Inc (2017–2025)
Cash flow-to-debt ratio of Greenwich Lifesciences Inc from 2017 to 2025. Historical debt coverage capacity for Greenwich Lifesciences Inc across 9 annual periods. Check GLSI capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Greenwich Lifesciences Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
Greenwich Lifesciences Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Greenwich Lifesciences Inc. For the full cash flow conversion analysis, see GLSI cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.70x | $-9.91 Million | $5.82 Million | ▲ +25.4% |
| 2024 | -2.28x | $-7.27 Million | $3.19 Million | ▲ +89.6% |
| 2023 | -22.01x | $-6.48 Million | $294.41K | ▲ +6.7% |
| 2022 | -23.58x | $-6.20 Million | $262.90K | ▼ -111.7% |
| 2021 | -11.14x | $-4.29 Million | $385.17K | ▼ -910.3% |
| 2020 | -1.10x | $-1.15 Million | $1.05 Million | ▼ -417.8% |
| 2019 | -0.21x | $-293.27K | $1.38 Million | ▼ -1795.0% |
| 2018 | -0.01x | $-114.95K | $10.23 Million | ▲ +20.4% |
| 2017 | -0.01x | $-120.85K | $8.56 Million | — |